BTG plc
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BTG plc
Destiny Joins AIM Exodus In Bid To Stay Afloat
Chairman Sir Nigel Rudd said re-registering as a private company is necessary to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials, without which “liquidation of the company is the most likely alternative.”
Gain Therapeutics Navigates Market Fluctuations While Developing Parkinson’s Treatment
Gain Therapeutics aims to offer a disease-modifying treatment for Parkinson’s patients with GCase mutations. The company’s promising data and platform face competition from notable rivals.
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
Finance Watch: Verona Accesses Up To $650m As Ensifentrine Approval Deadline Nears
Public Company Edition: Verona Pharma arranged up to $400m in new debt and up to $250m in revenue-related financing ahead of its COPD drug launch. Also, Organon, Sobi and Pacira priced $1bn, $275.1m and $250m note sales, respectively. Marinus, Emergent and Ginkgo cut jobs.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Biocompatibles International plc
- CellMed
- Ekos Corporation
- Galil Medical, Inc.
- Novate Medical Ltd.
- PneumRx Inc.
- Protherics PLC
- Roxwood Medical
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice